

TABLE OF CONTENTS

Book 10

Preface	i
Editorial Board	ii
Book 10 Panel	iii
Disclosure of Potential Conflicts of Interest	vii
Continuing Education and Program Evaluation Instructions	viii
Roles of ACCP and BPS	xi

Hematology

ADULT ACUTE LEUKEMIAS

Learning Objectives	1
Introduction	1
Acute Myelogenous Leukemias	2
Pathophysiology	2
Epidemiology	2
Etiology	2
Clinical Presentation	2
Laboratory Examination and Diagnosis	2
Prognosis	3
Classification	3
Quality Pharmaceutical Care of Acute Myeloid Leukemia	3
Treatment Overview	3
Treatment Plan	3
Induction Therapy	3
Assessment of Treatment Response	5
Post-Remission Therapy	5
Therapeutic Considerations	5
Recurrent AML	6
Acute Promyelocytic Leukemia	6

Acute Lymphocytic Leukemia	6
Pathophysiology	6
Epidemiology	7
Etiology	7
Clinical Presentation	7
Laboratory Examination and Diagnosis	7
Classification	7
Prognosis	7
Quality Pharmaceutical Care of Acute Lymphocytic Leukemia	7
Treatment Overview	7
Treatment Plan	7
Assessment of Treatment Response	8
Post-Remission Therapy	8
Imatinib in Philadelphia Chromosome Positive ALL ..	9
Chemotherapy Toxicity Monitoring	9
Cytarabine	9
L-asparaginase	10
Anthracycline	10
Vincristine	10
Methotrexate	10
Conclusion	11
Annotated Bibliography	11
Self-Assessment Questions	13

HEMOPHILIAS AND THROMBOPHILIAS

Learning Objectives	17
Introduction	17
Mechanisms of Hemostasis	17
Vascular Wall	18
Platelets	18
Coagulation System	19
Procoagulants	19
Anticoagulants	20
Fibrinolysis	21
Hemophilias	21
History	21
Congenital Disorders	22
Hemophilia A and B	22

von Willebrand Disease	.22
Management of Bleeding Episodes	.22
Desmopressin	.23
Factor Concentrates	.24
Ancillary Therapies	.25
Gene Therapy	.25
Inhibitors to Coagulation Factors	.26
Prevalence and Clinical Course	.26
Managing Bleeding Episodes	.26
Activated Prothrombin Complex Concentrates	.27
Recombinant Factor VIIa	.27
Combination Therapy	.28
Eradication Approaches	.28
Immune Tolerance	.28
Immune Modulation	.29
Pharmacoeconomics	.29
Thrombophilias	.29
Overview	.29
Activated Protein C Resistance/Factor V Leiden	.29
Prothrombin Gene Mutation	.30
Protein C Deficiency	.30
Protein S Deficiency	.30
Hyperhomocysteinemia	.31
Antiphospholipid Antibody Syndrome	.31
Summary	.32
Conclusion	.32
Annotated Bibliography	.32
Self-Assessment Questions	.33

MULTIPLE MYELOMA

Learning Objectives	.37
Introduction	.37
Epidemiology	.37
Etiology	.37
Risk Factors	.38
Signs and Symptoms	.38
Diagnosis	.39
Staging	.39
Prognostic Factors	.39
Treatment	.40
Induction Therapy	.40
Role of Stem Cell Transplantation	.42
Maintenance Therapy	.44
Therapy for Relapsed or Refractory Disease	.45
Monitoring Plan	.45
Supportive Therapy	.45
Conclusion	.46
Annotated Bibliography	.47
Self-Assessment Questions	.49

Oncology I

MELANOMA

Learning Objectives	.55
Introduction	.55
Epidemiology	.55

Pathophysiology of Melanoma	.56
Definitions	.56
Pathogenic Effects of Ultraviolet Light	.56
Sunscreens and Prevention	.57
Immunologic Influence	.58
Patient Risk Factors	.59
Sun Exposure	.59
Phenotypic Traits	.59
Inherited Traits	.59
Special Populations	.60
Patients With Solid Organ Transplant	.60
Patients With Human Immunodeficiency Virus	.60
Clinical Characteristics	.60
Presentation	.60
Pathologic Subtypes	.60
Superficial Spreading Melanoma	.61
Nodular Melanoma	.61
Lentigo Maligna Melanoma	.61
Acral Lentiginous Melanoma	.61
Diagnosis	.61
Staging and Prognosis	.62
Quality Pharmaceutical Care	.62
Treatment Plan	.63
Nonpharmacological Treatment	.63
Surgery	.63
Radiation Therapy	.63
Pharmacological Therapy	.63
Adjuvant Therapy	.63
Interferon- α 2b	.64
Vaccines	.65
Treatment of Advanced Melanoma	.65
Single-Agent Systemic Chemotherapy	.65
Dacarbazine	.66
Temozolomide	.66
Nitrosoureas	.66
Platinum Anticancer Drugs	.67
Taxanes	.68
Other Single-Agent Chemotherapies	.68
Combination Chemotherapy	.69
Nitrosourea and DTIC-Based Combination Therapies	.69
Taxane-Based Combination Therapy	.69
Cisplatin-Based Combination Therapy	.69
Tamoxifen-Based Therapy	.71
Single-Agent Immunotherapy	.72
Interleukin-2	.72
Combination Biochemotherapy	.72
Interferon- α 2b-Based Biochemotherapy Regimens	.72
Interleukin-2-Based Biochemotherapy Regimens	.72
Vaccines	.73
Future Directions	.75
Special Populations	.75
Patients with Solid Organ Transplant	.75
Patients Infected with HIV	.76

Early Screening and Prevention	.76	LUNG CANCER	
Chemoprevention	.76	Learning Objectives	.105
Patient Education	.77	Introduction	.105
Quality Improvement	.77	Small Cell Lung Cancer and Non-Small Cell Lung Cancer	.105
Response and Survival	.77	Role of the Pharmacist	.106
Efficacy	.77	Small Cell Lung Cancer	.106
Efficiency	.77	Treatment of Small Cell Lung Cancer	.107
Effectiveness	.78	Newer Drugs for Small Cell Lung Cancer	.109
Pharmacoeconomics	.78	Paraneoplastic Syndromes	.110
The Pharmacists' Role	.78	Non-Small Cell Lung Cancer	.110
Conclusion	.79	Treatment of Non-Small Cell Lung Cancer:	
Annotated Bibliography	.79	Resectable Disease	.111
Self-Assessment Questions	.81	Treatment of NSCLC: Unresectable and Advanced Disease	.111
OVARIAN CANCER		Newer Drugs for NSCLC	.114
Learning Objectives	.85	Tobacco Research	.116
Introduction	.85	Mesothelioma	.116
Epidemiology	.85	Staging and Prognostic Factors	.116
Pathophysiology	.86	Treatment of Malignant Pleural Mesothelioma	.116
Etiology	.86	Conclusion	.117
Pathogenesis	.86	Annotated Bibliography	.117
Histological Classification	.86	Self-Assessment Questions	.119
Clinical Evaluation	.87	PROSTATE CANCER	
Presentation	.87	Learning Objectives	.123
Screening	.87	Introduction	.123
Diagnosis	.87	Prostate Cancer Risk Factors	.123
Staging	.87	Race and Heredity	.123
Prognosis	.88	Diet and Prevention	.124
Treating Epithelial Ovarian Cancer	.88	Chemoprevention	.124
Role of Surgery	.88	Prognosis Prediction	.125
Role of Radiation	.89	High-Risk Prostate Cancer	.125
Managing Early Disease	.89	Early Detection	.125
Management of Advanced Disease	.89	Prostate-Specific Antigen	.126
Adjuvant Chemotherapy	.90	Digital Rectal Examination	.127
Neoadjuvant Treatment	.91	Screening Strategies	.127
Consolidation Treatment	.91	Pathophysiology	.127
Intraperitoneal Therapy	.92	Prostate Pathology	.127
Assessment of Response	.92	Histology	.128
Refractory, Resistant, and Recurrent Disease	.93	Staging	.128
Refractory and Resistant Disease	.93	Molecular Biology	.128
Late Recurrence	.93	Treatment of Prostate Cancer	.128
Second-Line Chemotherapy	.93	Primary Treatment	.128
Patient-Related Considerations	.93	Expectant Management	.129
Drug Selection	.94	Local Therapy	.129
High-Dose Chemotherapy	.95	Complications of Local Therapy	.131
Current Research	.95	Adjuvant and Neoadjuvant Therapy	.131
Nonepithelial Ovarian Cancer	.95	Secondary or Salvage Therapy	.132
Supportive Care Issues	.96	Androgen Ablation	.132
Effects of Ovariectomy	.96	Antiandrogens	.133
Adverse Effects of Drug Treatment	.96	Combined Androgen Blockade	.134
Managing Disease Complications	.97	Therapy for Relapsed Disease	.134
Psychosocial Issues	.98	Systemic Hormonal Therapy	.134
Quality Improvement	.98	Systemic Chemotherapy	.135
Author's Note	.99	Symptom Management	.137
Annotated Bibliography	.99		
Self-Assessment Questions	.101		

Bone Pain	137
Spinal Cord Compression	138
Future Directions	138
Pharmaceutical Care of the Patient with Prostate Cancer	139
Annotated Bibliography	140
Self-Assessment Questions	141

Oncology II

INFECTIONS IN PATIENTS WITH CANCER

Learning Objectives	147
Introduction	147
Impaired Host Defenses in Patients With Cancer	147
Impaired Neutrophil Function	147
Impaired Cellular and Humoral Immunity	148
Disruption of Skin and Mucosal Barriers	148
Impaired Reticuloendothelial Function	149
Pathogens Infecting Patients with Cancer	149
Etiology of Infections in Patients with Cancer	149
Pathogens Isolated From Infected Patients	149
Bacterial Pathogens	149
Fungal Pathogens	150
Viral Pathogens	150
<i>Pneumocystis jiroveci</i>	150
Clinical Presentation of Infection in Patients with Cancer	150
Diagnosis—Signs and Symptoms	150
Risk Assessment	151
Empiric Antibiotic Therapy—Initiation and Monitoring	151
Empiric Vancomycin	152
Management of VAD Infections	153
Treatment of VRE	153
Broad-Spectrum Monotherapy	154
Broad-Spectrum Combination Therapy	155
Empiric Antifungal Therapy	156
Amphotericin B Products	156
Itraconazole	156
Voriconazole	157
Caspofungin	157
Duration of Antimicrobial Therapy	158
Treatment of <i>Pneumocystis jiroveci</i> Pneumonia	159
Treatment of Viral Infections	159
Prophylactic Antimicrobial Therapy	160
Bacterial Prophylaxis	160
PCP Prophylaxis	160
Fungal Prophylaxis	160
Viral Prophylaxis	161
Use of Colony-Stimulating Factors	161
Conclusion	163
Annotated Bibliography	163
Self-Assessment Questions	165

SUPPORTIVE CARE OF THE CANCER PATIENT

Learning Objectives	171
---------------------	-----

Introduction	171
Chemotherapy-Induced Nausea and Vomiting	171
Pathophysiology	172
Definition	172
Etiology	172
Clinical Characteristics	172
Epidemiology	172
Therapeutic Goals	173
Quality Patient Care	173
Pharmacotherapy	173
General Principles	173
Dexamethasone	175
Aprepitant	175
Palonosetron	176
Olanzapine	176
Nondrug Therapy	176
Treatment Plan	177
Antiemetic Guidelines	177
Antiemetic Treatment in Special Populations	177
Patients Without Prescription Drug Benefits	177
Multiday Chemotherapy Regimens	177
Optimizing Antiemetic Therapy	178
Monitoring, Documentation, and Patient Education	178
Quality Improvement	179
Mucositis	179
Pathophysiology	179
Definition	179
Etiology	180
Clinical Characteristics and Prognosis	180
Epidemiology	180
Therapeutic Goals	180
Quality Patient Care	181
Pharmacotherapy	181
Prevention of Mucositis and Promotion of Healing	181
Pain Relief	181
Prevention and Treatment of Secondary Infections	182
Prevention and Treatment of Dehydration and Malnutrition	182
New Therapies in the Prevention and Treatment of OM	182
Palifermin	182
Repifermin	183
Glutamine Novel Formulation	183
Benzylamine	183
Low-Level Laser Therapy	183
Treatment Plan and Patient Education	183
Patient Education	183
Cancer-Related Fatigue	183
Pathophysiology	183
Definition	183
Etiology	184
Clinical Characteristics	185
Epidemiology and Prognosis	185

Therapeutic Goals	185
Quality Patient Care	185
Pharmacological and Nonpharmacological	
Treatments	185
Poor Pain Control	185
Depression and Emotional Distress	185
Sleep Disturbances	186
Anemia	186
Poor Nutritional Status	187
Reduced Physical Activity and Deconditioning ..	187
Comorbidities and Drugs	187
Psychostimulants	187
Treatment Plan	188
Therapeutic Goals	188
Treatment Approach	188
Monitoring, Documentation, and Patient	
Education	189
Quality Improvement	189
Conclusion	189
Annotated Bibliography	189
Self-Assessment Questions	191